Phathom Pharmaceuticals, Inc.

NasdaqGS:PHAT Stock Report

Market Cap: US$572.3m

Phathom Pharmaceuticals Future Growth

Future criteria checks 5/6

Phathom Pharmaceuticals is forecast to grow earnings and revenue by 54.1% and 53% per annum respectively while EPS is expected to grow by 55% per annum.

Key information

54.1%

Earnings growth rate

55.0%

EPS growth rate

Pharmaceuticals earnings growth24.1%
Revenue growth rate53.0%
Future return on equityn/a
Analyst coverage

Good

Last updated11 Dec 2024

Recent future growth updates

Recent updates

Phathom Pharmaceuticals: The Large Drop Is, Well, Unfathomable

Dec 11

Following Up On Phathom Pharmaceuticals

Sep 03

Phathom Pharmaceuticals: Time To Deliver Promise Of Voquezna After Frustrating Delays

Jun 26

Phathom: Undervalued Biotech With Possible GERD Treatment Label Expansion

Mar 18

Phathom Pharmaceuticals GAAP EPS of -$1.33 misses by $0.30

Aug 02

The Prognosis For Phathom Pharmaceuticals

Jun 22

Phathom Pharmaceuticals: Undiscovered Gem

Jan 20

Phathom Pharma prices equity offering at $42

Dec 17

Phathom Pharma launches equity offering

Dec 15

Phantom Pharma completes enrollment in late-stage study of lead candidate in esophagus inflammation disorder

Nov 30

Earnings and Revenue Growth Forecasts

NasdaqGS:PHAT - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2026384-151-156N/A6
12/31/2025175-321-231-2127
12/31/202451-348-283-2847
9/30/202426-339-248-247N/A
6/30/202410-297-217-215N/A
3/31/20243-247-168-167N/A
12/31/20231-202-139-138N/A
9/30/2023N/A-177-136-135N/A
6/30/2023N/A-185-139-138N/A
3/31/2023N/A-195-143-141N/A
12/31/2022N/A-198-148-147N/A
9/30/2022N/A-179-147-147N/A
6/30/2022N/A-164-141-141N/A
3/31/2022N/A-150-144-143N/A
12/31/2021N/A-144-149-148N/A
9/30/2021N/A-162-136-135N/A
6/30/2021N/A-159-128-127N/A
3/31/2021N/A-144-109-108N/A
12/31/2020N/A-129-71-70N/A
9/30/2020N/A-173-66-65N/A
6/30/2020N/A-207-52-51N/A
3/31/2020N/A-274-73-47N/A
12/31/2019N/A-255-62-37N/A
9/30/2019N/A-158-39-13N/A
6/30/2019N/A-90-32-7N/A
3/31/2019N/A-2-2-2N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: PHAT is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.6%).

Earnings vs Market: PHAT is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: PHAT is expected to become profitable in the next 3 years.

Revenue vs Market: PHAT's revenue (53% per year) is forecast to grow faster than the US market (9.1% per year).

High Growth Revenue: PHAT's revenue (53% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if PHAT's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/18 22:50
End of Day Share Price 2024/12/18 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Phathom Pharmaceuticals, Inc. is covered by 11 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullBMO Capital Markets Equity Research
Chase KnickerbockerCraig-Hallum Capital Group LLC
Umer RaffatEvercore ISI